Upbeat Zydus takes its glitazar into lipodystrophy
This article was originally published in Scrip
Executive Summary
Zydus Cadila has begun studies for a new indication – lipodystrophy –with its glitazar, Lipaglyn (saroglitazar), currently approved in India for the treatment of dyslipidemia or hypertriglyceridemia not controlled by statins alone in patients with type 2 diabetes.